Form 4 · Filed Jun 11, 2026, 08:32 PM UTC
KALV/KalVista Pharmaceuticals, Inc.
Sweeny Nicole — Chief Commercial Officer
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
5 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | D | other | 59,291 | $0 | — | 0 |
| Jun 11, 2026 | D | other | 100,000 | — | — | 0 |
| Jun 11, 2026 | D | other | 40,000 | — | — | 0 |
| Jun 11, 2026 | D | other | 68,750 | — | — | 0 |
| Jun 11, 2026 | D | other | 93,750 | — | — | 0 |
Source: SEC EDGAR raw filing ↗ · Accession 0001827505-26-000007